BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its stake in Pfizer Inc. by 22.2% during the 3rd quarter, selling 1,680,468 shares. Despite this, other institutional investors have increased their holdings, and analysts have mixed ratings on Pfizer, with an average “Hold” rating and a target price of $27.84. Pfizer recently reported strong Q4 earnings, beating analyst estimates, and announced a quarterly dividend of $0.43 per share.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Position in Pfizer Inc. $PFE
BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its stake in Pfizer Inc. by 22.2% during the 3rd quarter, selling 1,680,468 shares. Despite this, other institutional investors have increased their holdings, and analysts have mixed ratings on Pfizer, with an average “Hold” rating and a target price of $27.84. Pfizer recently reported strong Q4 earnings, beating analyst estimates, and announced a quarterly dividend of $0.43 per share.